Evidence map›Paper›PMID 37592824›Full record

SynthesisThe Journal of infectious diseases2023

Geographic and Population Distributions of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Circulating Subtypes: A Systematic Literature Review and Meta-analysis (2010-2021).

Alexandria Williams, Sonia Menon, Madeleine Crowe, Neha Agarwal, Jorne Biccler, Nicholas Bbosa, Deogratius Ssemwanga, Ferdinard Adungo, Christiane Moecklinghoff, Malcolm Macartney and 1 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandria WilliamsP95 Pharmacovigilance and Epidemiological Services, Leuven, Belgium.ORCID 0000-0002-8244-5040
Sonia MenonP95 Pharmacovigilance and Epidemiological Services, Leuven, Belgium.ORCID 0000-0002-4422-1185
Madeleine CroweP95 Pharmacovigilance and Epidemiological Services, Leuven, Belgium.
Neha AgarwalP95 Pharmacovigilance and Epidemiological Services, Leuven, Belgium.
Jorne BicclerP95 Pharmacovigilance and Epidemiological Services, Leuven, Belgium.ORCID 0000-0002-8180-3782
Nicholas BbosaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.ORCID 0000-0003-1280-675X
Deogratius SsemwangaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.ORCID 0000-0001-9675-4234
Ferdinard AdungoKenya Medical Research Institute, Nairobi.ORCID 0000-0002-0873-7993
Christiane MoecklinghoffJanssen-Cilag GmbH, Neuss, Germany.
Malcolm MacartneyJanssen-Cilag Limited, High Wycombe, United Kingdom.ORCID 0000-0003-0852-8611
Valerie Oriol-MathieuJanssen Vaccines and Prevention, B.V., Leiden, The Netherlands.ORCID 0000-0003-4734-1729

Funding

Medical Research Council MC_UU_00033/1
6 · The paper itself

Abstract

backgroundHIV poses significant challenges for vaccine development due to its high genetic mutation and recombination rates. Understanding the distribution of HIV subtypes (clades) across regions and populations is crucial. In this study, a systematic review of the past decade was conducted to characterize HIV-1/HIV-2 subtypes.

methodsA comprehensive search was performed in PubMed, EMBASE, and CABI Global Health, yielding 454 studies from 91 countries.

resultsGlobally, circulating recombinant forms (CRFs)/unique recombinant forms (URFs) accounted for 29% of HIV-1 strains, followed by subtype C (23%) and subtype A (17%). Among studies reporting subtype breakdowns in key populations, 62% of HIV infections among men who have sex with men (MSM) and 38% among people who inject drugs (PWIDs) were CRF/URFs. Latin America and the Caribbean exhibited a 25% increase in other CRFs (excluding CRF01_AE or CRF02_AG) prevalence between 2010-2015 and 2016-2021.

conclusionsThis review underscores the global distribution of HIV subtypes, with an increasing prevalence of CRFs and a lower prevalence of subtype C. Data on HIV-2 were limited. Understanding subtype diversity is crucial for vaccine development, which need to elicit immune responses capable of targeting various subtypes. Further research is needed to enhance our knowledge and address the challenges posed by HIV subtype diversity.

Indexed as

HIV-1HIV InfectionsSexual and Gender MinoritiesGenetic VariationGenotypeHIV-2Homosexuality, MaleHumansMalePhylogenyPrevalenceepidemiologyHIV-1HIV-2HIV subtypesprevalence

Identifiers

PMID37592824
PMCPMC10681860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.